{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:59:56Z","timestamp":1793699996436,"version":"4.5.1"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41569-025-01244-w","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T02:11:03Z","timestamp":1767319863000},"page":"433-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimizing cardiovascular pharmacotherapy in older adults with frailty"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-8920","authenticated-orcid":false,"given":"Tu N.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-5296","authenticated-orcid":false,"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad H.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"1244_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/21551197.2011.623931","volume":"30","author":"RA Heuberger","year":"2011","unstructured":"Heuberger, R. A. The frailty syndrome: a comprehensive review. J. Nutr. Gerontol. Geriatrics 30, 315\u2013368 (2011).","journal-title":"J. Nutr. Gerontol. Geriatrics"},{"key":"1244_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg, A., Young, J., Iliffe, S., Rikkert, M. O. & Rockwood, K. Frailty in elderly people. Lancet 381, 752\u2013762 (2013).","journal-title":"Lancet"},{"key":"1244_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/j.1532-5415.2006.00738.x","volume":"54","author":"K Rockwood","year":"2006","unstructured":"Rockwood, K., Mitnitski, A., Song, X., Steen, B. & Skoog, I. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J. Am. Geriatrics Soc. 54, 975\u2013979 (2006).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR4","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried, L. P. et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146\u2013M156 (2001).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"1244_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","volume":"391","author":"DH Kim","year":"2024","unstructured":"Kim, D. H. & Rockwood, K. Frailty in older adults. N. Engl. J. Med. 391, 538\u2013548 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1244_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1159\/000211949","volume":"55","author":"PO Lang","year":"2009","unstructured":"Lang, P. O., Michel, J. P. & Zekry, D. Frailty syndrome: a transitional state in a dynamic process. Gerontology 55, 539\u2013549 (2009).","journal-title":"Gerontology"},{"key":"1244_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-8-24","volume":"8","author":"SD Searle","year":"2008","unstructured":"Searle, S. D., Mitnitski, A., Gahbauer, E. A., Gill, T. M. & Rockwood, K. A standard procedure for creating a frailty index. BMC Geriatr. 8, 24 (2008).","journal-title":"BMC Geriatr."},{"key":"1244_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cger.2010.08.008","volume":"27","author":"K Rockwood","year":"2011","unstructured":"Rockwood, K. & Mitnitski, A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin. Geriatric Med. 27, 17\u201326 (2011).","journal-title":"Clin. Geriatric Med."},{"key":"1244_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jacc.2021.11.029","volume":"79","author":"N Ijaz","year":"2022","unstructured":"Ijaz, N. et al. Interventions for frailty among older adults with cardiovascular disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 482\u2013503 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1244_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031736","volume":"13","author":"K James","year":"2024","unstructured":"James, K. et al. Frailty and cardiovascular health. J. Am. Heart Assoc. 13, e031736 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1244_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ageing\/afaa219","volume":"50","author":"R O\u2019Caoimh","year":"2021","unstructured":"O\u2019Caoimh, R. et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing 50, 96\u2013104 (2021).","journal-title":"Age Ageing"},{"key":"1244_CR12","first-page":"226","volume":"54","author":"R O\u2019Caoimh","year":"2018","unstructured":"O\u2019Caoimh, R. et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. Ann. Ist. Super. Sanita 54, 226\u2013238 (2018).","journal-title":"Ann. Ist. Super. Sanita"},{"key":"1244_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ageing\/afn293","volume":"38","author":"V Perera","year":"2009","unstructured":"Perera, V., Bajorek, B. V., Matthews, S. & Hilmer, S. N. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 38, 156\u2013162 (2009).","journal-title":"Age Ageing"},{"key":"1244_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/eurjpc\/zwaa167","volume":"29","author":"D Richter","year":"2022","unstructured":"Richter, D. et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur. J. Prev. Cardiol. 29, 216\u2013227 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1244_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.arr.2017.01.003","volume":"35","author":"N Veronese","year":"2017","unstructured":"Veronese, N. et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: results from a meta-analysis and exploratory meta-regression analysis. Ageing Res. Rev. 35, 63\u201373 (2017).","journal-title":"Ageing Res. Rev."},{"key":"1244_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/gerona\/gln026","volume":"64","author":"AR Cappola","year":"2009","unstructured":"Cappola, A. R., Xue, Q. L. & Fried, L. P. Multiple hormonal deficiencies in anabolic hormones are found in frail older women: the Women\u2019s Health and Aging studies. J. Gerontol. A Biol. Sci. Med. Sci. 64, 243\u2013248 (2009).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"1244_CR17","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1210\/jc.2009-2754","volume":"95","author":"Z Hyde","year":"2010","unstructured":"Hyde, Z. et al. Low free testosterone predicts frailty in older men: the health in men study. J. Clin. Endocrinol. Metab. 95, 3165\u20133172 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1244_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s12603-011-0130-5","volume":"15","author":"J Mulero","year":"2011","unstructured":"Mulero, J., Zafrilla, P. & Martinez-Cacha, A. Oxidative stress, frailty and cognitive decline. J. Nutr. Health Aging 15, 756\u2013760 (2011).","journal-title":"J. Nutr. Health Aging"},{"key":"1244_CR19","doi-asserted-by":"publisher","first-page":"M158","DOI":"10.1093\/gerona\/56.3.M158","volume":"56","author":"AB Newman","year":"2001","unstructured":"Newman, A. B. et al. Associations of subclinical cardiovascular disease with frailty. J. Gerontol. A Biol. Sci. Med. Sci. 56, M158\u2013M166 (2001).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"1244_CR20","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1093\/eurheartj\/ehab468","volume":"42","author":"AA Damluji","year":"2021","unstructured":"Damluji, A. A. et al. Frailty and cardiovascular outcomes in the National Health and Aging Trends Study. Eur. Heart J. 42, 3856\u20133865 (2021).","journal-title":"Eur. Heart J."},{"key":"1244_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/eurheartj\/ehab850","volume":"43","author":"W Shrauner","year":"2021","unstructured":"Shrauner, W. et al. Frailty and cardiovascular mortality in more than 3 million US Veterans. Eur. Heart J. 43, 818\u2013826 (2021).","journal-title":"Eur. Heart J."},{"key":"1244_CR22","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1161\/CIRCULATIONAHA.111.025452","volume":"124","author":"N Ekerstad","year":"2011","unstructured":"Ekerstad, N. et al. Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction. Circulation 124, 2397\u20132404 (2011).","journal-title":"Circulation"},{"key":"1244_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijcard.2015.03.334","volume":"187","author":"M Bo","year":"2015","unstructured":"Bo, M. et al. Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: a prospective observational study. Int. J. Cardiol. 187, 123\u2013125 (2015).","journal-title":"Int. J. Cardiol."},{"key":"1244_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/CIRCULATIONAHA.108.841437","volume":"121","author":"DH Lee","year":"2010","unstructured":"Lee, D. H., Buth, K. J., Martin, B. J., Yip, A. M. & Hirsch, G. M. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation 121, 973\u2013978 (2010).","journal-title":"Circulation"},{"key":"1244_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/CIRCOUTCOMES.111.961375","volume":"4","author":"M Singh","year":"2011","unstructured":"Singh, M. et al. Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization. Circ. Cardiovasc. Qual. Outcomes 4, 496\u2013502 (2011).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"1244_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/bjs.9785","volume":"102","author":"GK Ambler","year":"2015","unstructured":"Ambler, G. K. et al. Effect of frailty on short- and mid-term outcomes in vascular surgical patients. Br. J. Surg. 102, 638\u2013645 (2015).","journal-title":"Br. J. Surg."},{"key":"1244_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/ageing\/afr179","volume":"41","author":"I Singh","year":"2012","unstructured":"Singh, I. et al. Predictors of adverse outcomes on an acute geriatric rehabilitation ward. Age Ageing 41, 242\u2013246 (2012).","journal-title":"Age Ageing"},{"key":"1244_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/rheumatology\/ket348","volume":"53","author":"F Cacciatore","year":"2014","unstructured":"Cacciatore, F. et al. Long-term mortality in frail elderly subjects with osteoarthritis. Rheumatology 53, 293\u2013299 (2014).","journal-title":"Rheumatology"},{"key":"1244_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00134-014-3253-4","volume":"40","author":"P Le Maguet","year":"2014","unstructured":"Le Maguet, P. et al. Prevalence and impact of frailty on mortality in elderly ICU patients: a prospective, multicenter, observational study. Intensive Care Med. 40, 674\u2013682 (2014).","journal-title":"Intensive Care Med."},{"key":"1244_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.52964\/AMJA.0290","volume":"12","author":"S Conroy","year":"2013","unstructured":"Conroy, S. & Dowsing, T. The ability of frailty to predict outcomes in older people attending an acute medical unit. Acute Med. 12, 74\u201376 (2013).","journal-title":"Acute Med."},{"key":"1244_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2362.2005.01572.x","volume":"35","author":"F Cacciatore","year":"2005","unstructured":"Cacciatore, F. et al. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur. J. Clin. Investig. 35, 723\u2013730 (2005).","journal-title":"Eur. J. Clin. Investig."},{"key":"1244_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00228-012-1387-2","volume":"69","author":"RE Hubbard","year":"2013","unstructured":"Hubbard, R. E., O\u2019Mahony, M. S. & Woodhouse, K. W. Medication prescribing in frail older people. Eur. J. Clin. Pharmacol. 69, 319\u2013326 (2013).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"1244_CR33","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s11606-024-08732-8","volume":"39","author":"A Yao","year":"2024","unstructured":"Yao, A., Gao, L., Zhang, J., Cheng, J. M. & Kim, D. H. Frailty as an effect modifier in randomized controlled trials: a systematic review. J. Gen. Intern. Med. 39, 1452\u20131473 (2024).","journal-title":"J. Gen. Intern. Med."},{"key":"1244_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1055\/s-0043-1770724","volume":"125","author":"Y Zheng","year":"2025","unstructured":"Zheng, Y. et al. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb. Haemost. 125, 166\u2013177 (2025).","journal-title":"Thromb. Haemost."},{"key":"1244_CR35","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1055\/s-0042-1756355","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti, G. F. et al. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry Phase II and III. Thromb. Haemost. 122, 2030\u20132041 (2022).","journal-title":"Thromb. Haemost."},{"key":"1244_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0043-1769735","volume":"124","author":"M Grymonprez","year":"2024","unstructured":"Grymonprez, M., Petrovic, M., De Backer, T. L., Steurbaut, S. & Lahousse, L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb. Haemost. 124, 135\u2013148 (2024).","journal-title":"Thromb. Haemost."},{"key":"1244_CR37","first-page":"224","volume":"86","author":"D Raphael","year":"1995","unstructured":"Raphael, D. et al. Frailty: a public health perspective. Can. J. Public. Health 86, 224\u2013227 (1995).","journal-title":"Can. J. Public. Health"},{"key":"1244_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.amjmed.2009.01.030","volume":"122","author":"B Kanapuru","year":"2009","unstructured":"Kanapuru, B. & Ershler, W. B. Inflammation, coagulation, and the pathway to frailty. Am. J. Med. 122, 605\u2013613 (2009).","journal-title":"Am. J. Med."},{"key":"1244_CR39","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/europace\/euac123","volume":"25","author":"I Savelieva","year":"2023","unstructured":"Savelieva, I. et al. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 25, 1249\u20131276 (2023).","journal-title":"Europace"},{"key":"1244_CR40","first-page":"176","volume":"7","author":"DM Walker","year":"2018","unstructured":"Walker, D. M. et al. Editor\u2019s choice \u2014 Frailty and the management of patients with acute cardiovascular disease: a position paper from the acute cardiovascular care association. Eur. Heart J. Acute Cardiovasc. Care 7, 176\u2013193 (2018).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"1244_CR41","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren, F. L. J. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for Cardiovascular Disease Prevention in Clinical Practice with representatives of the European society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur. Heart J. 42, 3227\u20133337 (2021).","journal-title":"Eur. Heart J."},{"key":"1244_CR42","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy, J. W. et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the Task Force on the Management of Elevated Blood Pressure and Hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur. Heart J. 45, 3912\u20134018 (2024).","journal-title":"Eur. Heart J."},{"key":"1244_CR43","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, e1082\u2013e1143 (2019).","journal-title":"Circulation"},{"key":"1244_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.mad.2019.111119","volume":"181","author":"SN Hilmer","year":"2019","unstructured":"Hilmer, S. N., Wu, H. & Zhang, M. Biology of frailty: implications for clinical pharmacology and drug therapy in frail older people. Mech. Ageing Dev. 181, 22\u201328 (2019).","journal-title":"Mech. Ageing Dev."},{"key":"1244_CR45","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/ageing\/22.5.354","volume":"22","author":"HA Wynne","year":"1993","unstructured":"Wynne, H. A. et al. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing 22, 354\u2013359 (1993).","journal-title":"Age Ageing"},{"key":"1244_CR46","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/ageing\/afab003","volume":"50","author":"SN Hilmer","year":"2021","unstructured":"Hilmer, S. N. & Kirkpatrick, C. M. J. New horizons in the impact of frailty on pharmacokinetics: latest developments. Age Ageing 50, 1054\u20131063 (2021).","journal-title":"Age Ageing"},{"key":"1244_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s41999-021-00481-9","volume":"12","author":"MB Zazzara","year":"2021","unstructured":"Zazzara, M. B., Palmer, K., Vetrano, D. L., Carf\u00ec, A. & Onder, G. Adverse drug reactions in older adults: a narrative review of the literature. Eur. Geriatr. Med. 12, 463\u2013473 (2021).","journal-title":"Eur. Geriatr. Med."},{"key":"1244_CR48","first-page":"215","volume":"10","author":"TD O\u2019Brien","year":"1968","unstructured":"O\u2019Brien, T. D., Roberts, J., Brackenridge, G. R. & Lloyd, W. H. Some aspects of community care of the frail and elderly: the need for assessment. Gerontol. Clin. 10, 215\u2013227 (1968).","journal-title":"Gerontol. Clin."},{"key":"1244_CR49","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1532-5415.1988.tb04398.x","volume":"36","author":"CH Winograd","year":"1988","unstructured":"Winograd, C. H., Gerety, M. B., Brown, E. & Kolodny, V. Targeting the hospitalized elderly for geriatric consultation. J. Am. Geriatrics Soc. 36, 1113\u20131119 (1988).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/irdr.2023.01113","volume":"13","author":"Y Deng","year":"2024","unstructured":"Deng, Y. & Sato, N. Global frailty screening tools: review and application of frailty screening tools from 2001 to 2023. Intractable Rare Dis. Res. 13, 1\u201311 (2024).","journal-title":"Intractable Rare Dis. Res."},{"key":"1244_CR51","doi-asserted-by":"publisher","first-page":"1066.e1","DOI":"10.1016\/j.jamda.2016.07.023","volume":"17","author":"RV Azzopardi","year":"2016","unstructured":"Azzopardi, R. V. et al. Linking frailty instruments to the international classification of functioning, disability, and health: a systematic review. J. Am. Med. Dir. Assoc. 17, 1066.e1\u20131066.e11 (2016).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1244_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12603-018-1123-4","volume":"23","author":"L Ma","year":"2019","unstructured":"Ma, L. Current situation of frailty screening tools for older adults. J. Nutr. Health Aging 23, 111\u2013118 (2019).","journal-title":"J. Nutr. Health Aging"},{"key":"1244_CR53","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.arr.2010.09.001","volume":"10","author":"NM de Vries","year":"2011","unstructured":"de Vries, N. M. et al. Outcome instruments to measure frailty: a systematic review. Ageing Res. Rev. 10, 104\u2013114 (2011).","journal-title":"Ageing Res. Rev."},{"key":"1244_CR54","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ageing\/afn011","volume":"37","author":"FC Martin","year":"2008","unstructured":"Martin, F. C. & Brighton, P. Frailty: different tools for different purposes? Age Ageing 37, 129\u2013131 (2008).","journal-title":"Age Ageing"},{"key":"1244_CR55","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jamda.2017.04.018","volume":"18","author":"E Dent","year":"2017","unstructured":"Dent, E. et al. The Asia-Pacific clinical practice guidelines for the management of frailty. J. Am. Med. Dir. Assoc. 18, 564\u2013575 (2017).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1244_CR56","first-page":"957","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2022","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398, 957\u2013980 (2022).","journal-title":"Lancet"},{"key":"1244_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024406","volume":"8","author":"DL Vetrano","year":"2018","unstructured":"Vetrano, D. L. et al. Hypertension and frailty: a systematic review and meta-analysis. BMJ Open. 8, e024406 (2018).","journal-title":"BMJ Open."},{"key":"1244_CR58","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson, J. D. et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: a randomized clinical trial. JAMA 315, 2673\u20132682 (2016).","journal-title":"JAMA"},{"key":"1244_CR59","unstructured":"National Institute for Health and Care and Excellence. Hypertension in Adults: Diagnosis and Management. NICE Guideline NG136. https:\/\/www.nice.org.uk\/guidance\/ng136 (NICE, 2023)."},{"key":"1244_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.7326\/M16-1785","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem, A. et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med. 166, 430\u2013437 (2017).","journal-title":"Ann. Intern. Med."},{"key":"1244_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5694\/mja16.00526","volume":"205","author":"GM Gabb","year":"2016","unstructured":"Gabb, G. M. et al. Guideline for the diagnosis and management of hypertension in adults \u2014 2016. Med. J. Aust 205, 85\u201389 (2016).","journal-title":"Med. J. Aust"},{"key":"1244_CR62","doi-asserted-by":"publisher","first-page":"E549","DOI":"10.1503\/cmaj.241770","volume":"197","author":"R Goupil","year":"2025","unstructured":"Goupil, R. et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ 197, E549\u2013E564 (2025).","journal-title":"CMAJ"},{"key":"1244_CR63","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000257","volume":"82","author":"DW Jones","year":"2025","unstructured":"Jones, D. W. et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 82, e212\u2013e316 (2025).","journal-title":"Hypertension"},{"key":"1244_CR64","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett, N. S. et al. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358, 1887\u20131898 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1244_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0328-1","volume":"13","author":"J Warwick","year":"2015","unstructured":"Warwick, J. et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 13, 78 (2015).","journal-title":"BMC Med."},{"key":"1244_CR66","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Trial of intensive blood-pressure control in older patients with hypertension. N. Engl. J. Med. 385, 1268\u20131279 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1244_CR67","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/jamainternmed.2022.1657","volume":"182","author":"T Chen","year":"2022","unstructured":"Chen, T. et al. Time to clinical benefit of intensive blood pressure lowering in patients 60 years and older with hypertension: a secondary analysis of randomized clinical trials. JAMA Intern. Med. 182, 660\u2013667 (2022).","journal-title":"JAMA Intern. Med."},{"key":"1244_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.7326\/M16-1754","volume":"166","author":"J Weiss","year":"2017","unstructured":"Weiss, J. et al. Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and meta-analysis. Ann. Intern. Med. 166, 419\u2013429 (2017).","journal-title":"Ann. Intern. Med."},{"key":"1244_CR69","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.2337\/dc25-S013","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee 13. Older adults: standards of care in diabetes \u2014 2025. Diabetes Care 48, S266\u2013S282 (2025).","journal-title":"Diabetes Care"},{"key":"1244_CR70","unstructured":"National Institute for Health and Care Excellence. Type 2 Diabetes in Adults: Management. NICE Guideline NG28 https:\/\/www.nice.org.uk\/guidance\/ng28 (NICE, 2022)."},{"key":"1244_CR71","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2337\/dc20-2664","volume":"44","author":"TN Nguyen","year":"2021","unstructured":"Nguyen, T. N. et al. The Impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care 44, 1622\u20131629 (2021).","journal-title":"Diabetes Care"},{"key":"1244_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/17446651.2022.2079495","volume":"17","author":"T Crabtree","year":"2022","unstructured":"Crabtree, T., Ogendo, J.-J., Vinogradova, Y., Gordon, J. & Idris, I. Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age \u226560 years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. Expert. Rev. Endocrinol. Metab. 17, 255\u2013267 (2022).","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"1244_CR73","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753\u20132786 (2022).","journal-title":"Diabetes Care"},{"key":"1244_CR74","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577\u20131589 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1244_CR75","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 41, 111\u2013188 (2019).","journal-title":"Eur. Heart J."},{"key":"1244_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","author":"F Mach","year":"2025","unstructured":"Mach, F. et al. 2025 focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190 (2025).","journal-title":"Eur. Heart J."},{"key":"1244_CR77","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/jgs.18700","volume":"72","author":"AR Orkaby","year":"2024","unstructured":"Orkaby, A. R. et al. New statin use, mortality, and first cardiovascular events in older US veterans by frailty status. J. Am. Geriatrics Soc. 72, 410\u2013422 (2024).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR78","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jamainternmed.2013.6184","volume":"173","author":"I Mansi","year":"2013","unstructured":"Mansi, I., Frei, C. R., Pugh, M. J., Makris, U. & Mortensen, E. M. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern. Med. 173, 1318\u20131326 (2013).","journal-title":"JAMA Intern. Med."},{"key":"1244_CR79","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jama.2023.2487","volume":"329","author":"SJ Hong","year":"2023","unstructured":"Hong, S. J. et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA 329, 1078\u20131087 (2023).","journal-title":"JAMA"},{"key":"1244_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069915","volume":"13","author":"S Zoungas","year":"2023","unstructured":"Zoungas, S. et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 13, e069915 (2023).","journal-title":"BMJ Open."},{"key":"1244_CR81","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/jgs.18312","volume":"71","author":"J Joseph","year":"2023","unstructured":"Joseph, J. et al. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. J. Am. Geriatrics Soc. 71, 1701\u20131713 (2023).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR82","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Lewington, S. et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370, 1829\u20131839 (2007).","journal-title":"Lancet"},{"key":"1244_CR83","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder, I. C. et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur. Heart J. 45, 3314\u20133414 (2024).","journal-title":"Eur. Heart J."},{"key":"1244_CR84","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/j.1532-5415.1998.tb06011.x","volume":"46","author":"G Mendelson","year":"1998","unstructured":"Mendelson, G. & Aronow, W. S. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J. Am. Geriatrics Soc. 46, 1423\u20131424 (1998).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR85","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/BF02598984","volume":"11","author":"MR Antani","year":"1996","unstructured":"Antani, M. R. et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J. Gen. Intern. Med. 11, 713\u2013720 (1996).","journal-title":"J. Gen. Intern. Med."},{"key":"1244_CR86","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.jacc.2005.06.077","volume":"46","author":"AL Waldo","year":"2005","unstructured":"Waldo, A. L., Becker, R. C., Tapson, V. F. & Colgan, K. J. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J. Am. Coll. Cardiol. 46, 1729\u20131736 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1244_CR87","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eurger.2013.10.013","volume":"5","author":"A Corvol","year":"2014","unstructured":"Corvol, A. et al. Use of anticoagulants for atrial fibrillation in older subjects across different countries: Cyprus, France, Netherlands, Norway. Eur. Geriatric Med. 5, 60\u201365 (2014).","journal-title":"Eur. Geriatric Med."},{"key":"1244_CR88","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1016\/j.archger.2010.10.024","volume":"52","author":"K Radholm","year":"2011","unstructured":"Radholm, K. et al. Atrial fibrillation (AF) and co-morbidity in elderly. A population based survey of 85 years old subjects. Arch. Gerontol. Geriatr. 52, e170\u2013e175 (2011).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"1244_CR89","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/eurheartj\/ehl208","volume":"27","author":"S Monte","year":"2006","unstructured":"Monte, S. et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur. Heart J. 27, 2217\u20132223 (2006).","journal-title":"Eur. Heart J."},{"key":"1244_CR90","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1161\/01.STR.31.6.1217","volume":"31","author":"N Cohen","year":"2000","unstructured":"Cohen, N. et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 31, 1217\u20131222 (2000).","journal-title":"Stroke"},{"key":"1244_CR91","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1445-5994.2001.00071.x","volume":"31","author":"SL Jackson","year":"2001","unstructured":"Jackson, S. L., Peterson, G. M., Vial, J. H., Daud, R. & Ang, S. Y. Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern. Med. J. 31, 329\u2013336 (2001).","journal-title":"Intern. Med. J."},{"key":"1244_CR92","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/STROKEAHA.123.044407","volume":"55","author":"M S\u00f8gaard","year":"2024","unstructured":"S\u00f8gaard, M. et al. Net clinical benefit of oral anticoagulation among frail patients with atrial fibrillation: nationwide cohort study. Stroke 55, 413\u2013422 (2024).","journal-title":"Stroke"},{"key":"1244_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101652","volume":"79","author":"M Proietti","year":"2022","unstructured":"Proietti, M. et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. Ageing Res. Rev. 79, 101652 (2022).","journal-title":"Ageing Res. Rev."},{"key":"1244_CR94","first-page":"3238","volume":"36","author":"F Andreotti","year":"2015","unstructured":"Andreotti, F. et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology working group on thrombosis. Eur. heart J. 36, 3238\u20133249 (2015).","journal-title":"Eur. heart J."},{"key":"1244_CR95","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1055\/s-0044-1786028","volume":"124","author":"A Winijkul","year":"2024","unstructured":"Winijkul, A., Kaewkumdee, P., Yindeengam, A., Lip, G. Y. H. & Krittayaphong, R. Clinical outcomes of patients with atrial fibrillation who survived from bleeding event: the results from COOL-AF Thailand registry. Thromb. Haemost. 124, 991\u20131002 (2024).","journal-title":"Thromb. Haemost."},{"key":"1244_CR96","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.acvd.2013.04.001","volume":"106","author":"O Hanon","year":"2013","unstructured":"Hanon, O. et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch. Cardiovasc. Dis. 106, 303\u2013323 (2013).","journal-title":"Arch. Cardiovasc. Dis."},{"key":"1244_CR97","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar, J. A. et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 149, e1\u2013e156 (2024).","journal-title":"Circulation"},{"key":"1244_CR98","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373\u2013498 (2020).","journal-title":"Eur. Heart J."},{"key":"1244_CR99","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/14779072.2023.2276892","volume":"21","author":"LA Verma","year":"2023","unstructured":"Verma, L. A., Penson, P. E., Akpan, A., Lip, G. Y. H. & Lane, D. A. Managing older people with atrial fibrillation and preventing stroke: a review of anticoagulation approaches. Expert. Rev. Cardiovasc. Ther. 21, 963\u2013983 (2023).","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"1244_CR100","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28500","volume":"5","author":"S Akashi","year":"2022","unstructured":"Akashi, S. et al. Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial. JAMA Netw. Open. 5, e2228500 (2022).","journal-title":"JAMA Netw. Open."},{"key":"1244_CR101","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/joim.13140","volume":"289","author":"GYH Lip","year":"2021","unstructured":"Lip, G. Y. H. et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J. Intern. Med. 289, 42\u201352 (2021).","journal-title":"J. Intern. Med."},{"key":"1244_CR102","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.7326\/M20-7141","volume":"174","author":"DH Kim","year":"2021","unstructured":"Kim, D. H. et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation. Ann. Intern. Med. 174, 1214\u20131223 (2021).","journal-title":"Ann. Intern. Med."},{"key":"1244_CR103","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ehjcvp\/pvad091","volume":"10","author":"M S\u00f8gaard","year":"2024","unstructured":"S\u00f8gaard, M., Ording, A. G., Skj\u00f8th, F., Larsen, T. B. & Nielsen, P. B. Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation. Eur. Heart J. Cardiovasc. Pharmacother. 10, 137\u2013146 (2024).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"1244_CR104","first-page":"279","volume":"149","author":"LPT Joosten","year":"2024","unstructured":"Joosten, L. P. T. et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation 149, 279\u2013289 (2024).","journal-title":"Circulation"},{"key":"1244_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105280","volume":"25","author":"MJ de Jong","year":"2024","unstructured":"de Jong, M. J. et al. Intra-individual variability of direct oral anticoagulant levels in frail older patients upon, during, and after acute hospitalization: the DOAC-FRAIL study. J. Am. Med. Dir. Assoc. 25, 105280 (2024).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1244_CR106","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/jgs.16992","volume":"69","author":"M Bendayan","year":"2021","unstructured":"Bendayan, M. et al. Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation. J. Am. Geriatrics Soc. 69, 1012\u20131018 (2021).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR107","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40266-018-0613-8","volume":"36","author":"R Nissan","year":"2019","unstructured":"Nissan, R. et al. Apixaban levels in octogenarian patients with non-valvular atrial fibrillation. Drugs Aging 36, 165\u2013177 (2019).","journal-title":"Drugs Aging"},{"key":"1244_CR108","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne, R. A. et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology (ESC). Eur. Heart J. 44, 3720\u20133826 (2023).","journal-title":"Eur. Heart J."},{"key":"1244_CR109","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints, C. et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the Task Force for the Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC) endorsed by the European association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 45, 3415\u20133537 (2024).","journal-title":"Eur. Heart J."},{"key":"1244_CR110","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine, G. N. et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non\u2013ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 134, e123\u2013e155 (2016).","journal-title":"Circulation"},{"key":"1244_CR111","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer, D. O. et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke 52, e364\u2013e467 (2021).","journal-title":"Stroke"},{"key":"1244_CR112","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.21037\/jtd.2019.12.87","volume":"12","author":"G Biondi-Zoccai","year":"2020","unstructured":"Biondi-Zoccai, G. et al. Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review. J. Thorac. Dis. 12, 1656\u20131664 (2020).","journal-title":"J. Thorac. Dis."},{"key":"1244_CR113","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.amjcard.2023.08.059","volume":"207","author":"D Ko","year":"2023","unstructured":"Ko, D. et al. Utilization of P2Y12 inhibitors in older adults with ST-elevation myocardial infarction and frailty. Am. J. Cardiol. 207, 245\u2013252 (2023).","journal-title":"Am. J. Cardiol."},{"key":"1244_CR114","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034529","volume":"13","author":"D Ko","year":"2024","unstructured":"Ko, D. et al. Frailty and clinical outcomes of ticagrelor versus clopidogrel in older adults with acute myocardial infarction. J. Am. Heart Assoc. 13, e034529 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1244_CR115","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.10144","volume":"5","author":"JS Berger","year":"2022","unstructured":"Berger, J. S. Aspirin for primary prevention \u2014 time to rethink our approach. JAMA Netw. 5, e2210144 (2022).","journal-title":"JAMA Netw."},{"key":"1244_CR116","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/heartjnl-2021-320154","volume":"108","author":"S Montgomery","year":"2022","unstructured":"Montgomery, S., Miedema, M. D. & Dodson, J. A. Aspirin and statin therapy for primary prevention of cardiovascular disease in older adults. Heart 108, 1090\u20131097 (2022).","journal-title":"Heart"},{"key":"1244_CR117","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00228-008-0499-1","volume":"64","author":"RE Hubbard","year":"2008","unstructured":"Hubbard, R. E., O\u2019Mahony, M. S., Calver, B. L. & Woodhouse, K. W. Plasma esterases and inflammation in ageing and frailty. Eur. J. Clin. Pharmacol. 64, 895\u2013900 (2008).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"1244_CR118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ageing\/18.1.39","volume":"18","author":"FM Williams","year":"1989","unstructured":"Williams, F. M., Wynne, H., Woodhouse, K. W. & Rawlins, M. D. Plasma aspirin esterase: the influence of old age and frailty. Age Ageing 18, 39\u201342 (1989).","journal-title":"Age Ageing"},{"key":"1244_CR119","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40119-016-0056-4","volume":"5","author":"TN Nguyen","year":"2016","unstructured":"Nguyen, T. N. et al. Effect of frailty and age on platelet aggregation and response to aspirin in older patients with atrial fibrillation: a pilot study. Cardiol. Ther. 5, 51\u201362 (2016).","journal-title":"Cardiol. Ther."},{"key":"1244_CR120","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620915994","volume":"26","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Liu, S., Wang, K. & Liu, H. Association of frailty with antiplatelet response among elderly Chinese patients with coronary artery disease undergoing percutaneous coronary intervention. Clin. Appl. Thromb. Hemost. 26, 1076029620915994 (2020).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"1244_CR121","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/jcsm.13306","volume":"14","author":"KM Talha","year":"2023","unstructured":"Talha, K. M. et al. Frailty and heart failure: state-of-the-art review. J. Cachexia Sarcopenia Muscle 14, 1959\u20131972 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1244_CR122","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059905","volume":"12","author":"Y Sharma","year":"2022","unstructured":"Sharma, Y., Horwood, C., Hakendorf, P. & Thompson, C. Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study. BMJ Open. 12, e059905 (2022).","journal-title":"BMJ Open."},{"key":"1244_CR123","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","volume":"25","author":"MS Usman","year":"2018","unstructured":"Usman, M. S. et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 25, 495\u2013502 (2018).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1244_CR124","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","volume":"140","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm, K. et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes \u2014 a systematic review. Diabetes Res. Clin. Pract. 140, 118\u2013128 (2018).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1244_CR125","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ehf2.14163","volume":"10","author":"T Hamada","year":"2023","unstructured":"Hamada, T. et al. Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction. ESC Heart Fail. 10, 223\u2013233 (2023).","journal-title":"ESC Heart Fail."},{"key":"1244_CR126","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1111\/jgs.18481","volume":"71","author":"YC Lee","year":"2023","unstructured":"Lee, Y. C. et al. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction. J. Am. Geriatr. Soc. 71, 3110\u20133121 (2023).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1244_CR127","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jchf.2021.12.004","volume":"10","author":"MS Khan","year":"2022","unstructured":"Khan, M. S. et al. Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT trial. JACC Heart Fail. 10, 266\u2013275 (2022).","journal-title":"JACC Heart Fail."},{"key":"1244_CR128","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026844","volume":"12","author":"T Kondo","year":"2023","unstructured":"Kondo, T. et al. Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. J. Am. Heart Assoc. 12, e026844 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"1244_CR129","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jacc.2022.06.037","volume":"80","author":"JH Butt","year":"2022","unstructured":"Butt, J. H. et al. Sacubitril\/valsartan and frailty in patients with heart failure and preserved ejection fraction. J. Am. Coll. Cardiol. 80, 1130\u20131143 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1244_CR130","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/ejhf.1832","volume":"22","author":"P Dewan","year":"2020","unstructured":"Dewan, P. et al. The prevalence and importance of frailty in heart failure with reduced ejection fraction \u2014 an analysis of PARADIGM-HF and ATMOSPHERE. Eur. J. Heart Fail. 22, 2123\u20132133 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1244_CR131","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 7, 845\u2013854 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1244_CR132","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"C Arnott","year":"2020","unstructured":"Arnott, C. et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J. Am. Heart Assoc. 9, e014908 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1244_CR133","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2022.12.015","volume":"82","author":"TW Yi","year":"2023","unstructured":"Yi, T. W. et al. Kidney and cardiovascular effects of canagliflozin according to age and sex: a post hoc analysis of the CREDENCE randomized clinical trial. Am. J. Kidney Dis. 82, 84\u201396.e1 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"1244_CR134","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/M21-4776","volume":"175","author":"JH Butt","year":"2022","unstructured":"Butt, J. H. et al. Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial. Ann. Intern. Med. 175, 820\u2013830 (2022).","journal-title":"Ann. Intern. Med."},{"key":"1244_CR135","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","volume":"146","author":"JH Butt","year":"2022","unstructured":"Butt, J. H. et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation 146, 1210\u20131224 (2022).","journal-title":"Circulation"},{"key":"1244_CR136","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcsm.13393","volume":"15","author":"AJS Coats","year":"2024","unstructured":"Coats, A. J. S. et al. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. J. Cachexia Sarcopenia Muscle 15, 412\u2013424 (2024).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1244_CR137","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glad181","volume":"79","author":"P Vart","year":"2024","unstructured":"Vart, P. et al. Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. J. Gerontol. A Biol. Sci. Med. Sci 79, glad181 (2024).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci"},{"key":"1244_CR138","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2215\/CJN.0000000000000498","volume":"19","author":"KJ Mayne","year":"2024","unstructured":"Mayne, K. J. et al. Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial. Clin. J. Am. Soc. Nephrol. 19, 1119\u20131129 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1244_CR139","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/jgs.19444","volume":"73","author":"TN Nguyen","year":"2025","unstructured":"Nguyen, T. N. et al. The efficacy and safety of canagliflozin by frailty status in participants of the CANVAS and CREDENCE trials. J. Am. Geriatrics Soc. 73, 1787\u20131796 (2025).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR140","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jgs.19138","volume":"73","author":"DH Kim","year":"2025","unstructured":"Kim, D. H., Cheslock, M., Sison, S. M., Orkaby, A. R. & Schwartz, A. W. eFrailty: making frailty assessment accessible to clinicians and researchers. J. Am. Geriatr. Soc. 73, 318\u2013322 (2025).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1244_CR141","doi-asserted-by":"publisher","first-page":"111","DOI":"10.22540\/JFSF-04-111","volume":"4","author":"E Kyriakou","year":"2019","unstructured":"Kyriakou, E., Tzefronis, D., Dagianta, G. & Triantafyllopoulos, I. K. Implementing frailty assessment into a healthcare system: a clinical opinion paper. J. Frailty Sarcopenia Falls 4, 111\u2013115 (2019).","journal-title":"J. Frailty Sarcopenia Falls"},{"key":"1244_CR142","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/jgs.19443","volume":"73","author":"MJR Aliberti","year":"2025","unstructured":"Aliberti, M. J. R., Arteaga-Vargas, D. F. & Avelino-Silva, T. J. Frailty matters \u2014 why isn\u2019t it guiding clinical decisions? J. Am. Geriatrics Soc. 73, 1665\u20131670 (2025).","journal-title":"J. Am. Geriatrics Soc."},{"key":"1244_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnha.2024.100265","volume":"28","author":"JG Ruiz","year":"2024","unstructured":"Ruiz, J. G. & Muscedere, J. The ethics of frailty: a need for consensus guidelines. J. Nutr. Health Aging 28, 100265 (2024).","journal-title":"J. Nutr. Health Aging"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01244-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:03:51Z","timestamp":1779278631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01244-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":143,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01244-w","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"27 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.V.McM. reports payments to Glasgow University, UK, for clinical trials and other research projects from Alynylam Pharmaceuticals, AstraZeneca, Bayer, the British Heart Foundation, Cardurion, Cytokinetics, the National Institute for Health \u2013 National Heart, Lung, and Blood Institute (NIH-NHLBI), Novartis and Roche; personal consultancy fees from Alynylam Pharmaceuticals, AnaCardio, AstraZeneca, Bayer, Biohaven Pharmaceuticals, Cardurion, Chugai Pharmaceuticals, Cytokinetics, DalCor Pharmaceuticals, Novartis, Protherics Medicine Developments and River BioMedics; and personal lecture fees from Alkem Metabolics, ARMGO Pharmaceuticals, AstraZeneca, At the Limits, Canadian Medical and Surgical Knowledge, Centrix Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Hikma Pharmaceuticals, Hilton Pharmaceuticals, Imagica Health, IMEDIC Pharmaceuticals Micro Labs, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceuticals, Lupin Pharmaceuticals, MCI India, Medscape\/Heart.Org., ProAdWise Communications, Radcliffe Cardiology, Regeneron, Sun Pharmaceuticals and Translational Medicine Academy. J.J.V.McM. is a member of Data Safety Monitoring Boards for WCG Clinical Services, and is a director of Global Clinical Trial Partners, which provides clinical trial services such as end point committees and educational programmes. G.Y.H.L. is a National Institute for Health and Care Research (NIHR) Senior Investigator. He is a consultant and speaker for Anthos, BMS\/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo (no fees are received personally). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}